Sickle cell disease

被引:0
作者
Distelmaier, L. [1 ,2 ]
Duehrsen, U. [2 ]
Dickerhoff, R.
机构
[1] Vivantes Klinikum Neukolln, Klin Innere Med Hamatol Onkol & Palliat Med, Rudower Str 48, D-12351 Berlin, Germany
[2] Univ Klinikum Essen, Klin Hamatol, Essen, Germany
来源
INTERNIST | 2020年 / 61卷 / 07期
关键词
Hemoglobin; sickle; beta-Globins; Hydroxycarbamide; Acute chest syndrome; Genetic therapy; HEMOLYTIC TRANSFUSION REACTION; MANAGEMENT; STROKE; HEMOGLOBINOPATHIES; GUIDELINES; RISK;
D O I
10.1007/s00108-020-00822-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The term "sickle cell disease" covers a group of genetic blood disorders caused by sickle hemoglobin (HbS) alone or in combination with other variants of the beta-globin locus. Sickle cell disease occurs frequently in sub-Saharan Africa, but is also common in Turkey, Greece, Sicily, the Middle East, India, and the Americas. Polymerization of deoxygenated sickle hemoglobin leads to decreased deformability of red blood cells. These altered erythrocytes can obstruct small blood vessels and cause acute episodes of pain, hemolytic anemia, and organ damage. Complications can vary between the different genotypes and it is important to be aware of the special features of the disease. Hydroxycarbamide has been shown to reduce the morbidity and mortality of patients with sickle cell disease. New drugs and novel treatment approaches such as gene therapy are currently being tested.
引用
收藏
页码:754 / 758
页数:5
相关论文
共 30 条
  • [1] Agastinoiotis M, 2013, SCI WORLD J, DOI [10.1155/2013/727905, DOI 10.1155/2013/727905]
  • [2] Haemoglobinopathies in Europe: health & migration policy perspectives
    Aguilar Martinez, Patricia
    Angastiniotis, Michael
    Eleftheriou, Androulla
    Gulbis, Beatrice
    Manu Pereira, Maria Del Mar
    Petrova-Benedict, Roumyana
    Vives Corrons, Joan-Lluis
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
  • [3] Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus
    Antoniani, Chiara
    Meneghini, Vasco
    Lattanzi, Annalisa
    Felix, Tristan
    Romano, Oriana
    Magrin, Elisa
    Weber, Leslie
    Pavani, Giulia
    El Hoss, Sara
    Kurita, Ryo
    Nakamura, Yukio
    Cradick, Thomas J.
    Lundberg, Ante S.
    Porteus, Matthew
    Amendola, Mario
    El Nemer, Wassim
    Cavazzana, Marina
    Mavilio, Fulvio
    Miccio, Annarita
    [J]. BLOOD, 2018, 131 (17) : 1960 - 1973
  • [4] Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects
    Davis, Bernard A.
    Allard, Shubha
    Qureshi, Amrana
    Porter, John B.
    Pancham, Shivan
    Win, Nay
    Cho, Gavin
    Ryan, Kate
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (02) : 179 - 191
  • [5] Factors associated with survival in a contemporary adult sickle cell disease cohort
    Elmariah, Hany
    Garrett, Melanie E.
    De Castro, Laura M.
    Jonassaint, Jude C.
    Ataga, Kenneth I.
    Eckman, James R.
    Ashley-Koch, Allison E.
    Telen, Marilyn J.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (05) : 530 - 535
  • [6] Genetic predictors for stroke in children with sickle cell anemia
    Flanagan, Jonathan M.
    Frohlich, Denise M.
    Howard, Thad A.
    Schultz, William H.
    Driscoll, Catherine
    Nagasubramanian, Ramamoorthy
    Mortier, Nicole A.
    Kimble, Amy C.
    Aygun, Banu
    Adams, Robert J.
    Helms, Ronald W.
    Ware, Russell E.
    [J]. BLOOD, 2011, 117 (24) : 6681 - 6684
  • [7] Garden MA, 2017, HAEMATOLOGICA, V104, P1710
  • [8] Sickle Cell Disease: Advances in Treatment
    Gardner, Renee V.
    [J]. OCHSNER JOURNAL, 2018, 18 (04) : 377 - 389
  • [9] Howard J, 2019, HEMATOL-AM SOC HEMAT, P505, DOI 10.1182/hematology.2019000055
  • [10] Therapy Insight: stroke risk and its management in patients with sickle cell disease
    Kirkham, Fenella J.
    [J]. NATURE CLINICAL PRACTICE NEUROLOGY, 2007, 3 (05): : 264 - 278